Extended Data Fig. 9: Tumor microenvironment.
a, Relationship between tumor content and total predicted immune cell content. b, Cox proportional hazards model of overall survival from advanced disease diagnosis for all patients with CIBERSORT scores (n=568), taking tumor type, immune cluster, and tumor content into consideration. n values for individual groups are shown by the N column. Horizontal lines indicate the 95% confidence interval. c, Shared TCRβ sequences. Samples are displayed around the perimeter, where width represents the frequency of the shared clone in each sample, and joining lines indicate clones shared between samples. The two samples sharing the dominant CSARESTSDPKNEQFF clonotype are identifiable as the two dominant light blue arcs. d, Summary of tumor types and immune checkpoint inhibitors patients received after their POG biopsy. Drug targets and combinations are listed in Methods. e, Probability of continued therapy for the immunotherapy-treated cohort based on exonic mutation burden (n=76) and combined T cell scores (n=57) (see Methods). The p value for e was determined using a log-rank test, and n for each group is displayed in the table under the curves. Tumor types and biopsy sites as described in Fig. 1. All statistical tests are two-sided.
